Abstract:AIM: To find a soluble and functional recombinant receptor-binding domain of severe acute respiratory syndrome-associated coronavirus (SARS-Cov), and to analyze its receptor binding ability.METHODS: Three fusion tags (glutathione S-transferase, GST; thioredoxin, Trx; maltose-binding protein, MBP), which preferably contributes to increasing solubility and to facilitating the proper folding of heteroprotein, were used to acquire the soluble and functional expression of RBD protein in Escherichia coli (BL21(DE3) and Rosetta-gamiB (DE3) strains). The receptor binding ability of the purified soluble RBD protein was then detected by ELISA and flow cytometry assay.RESULTS: RBD of SARS-Cov spike protein was expressed as inclusion body when fused as TrxA tag form in both BL21 (DE3) and Rosetta-gamiB (DE3) under many different cultures and induction conditions. And there was no visible expression band on SDS-PAGE when RBD was expressed as MBP tagged form. Only GST tagged RBD was soluble expressed in BL21(DE3), and the protein was purified by ZKTA Prime Chromatography system. The ELISA data showed that GST.RBD antigen had positive reaction with anti-RBD mouse monoclonal antibody 1A5. Further flow cytometry assay demonstrated the high efficiency of RBD's binding ability to ACE2 (angiotensin-converting enzyme 2) positive Vero E6 cell. And ACE2 was proved as a cellular receptor that meditated an initial-affinity interaction with SARS-Cov spike protein. The geometrical mean of GST and GST.RBD binding to Vero E6 cells were 77.08 and 352.73 respectively.CONCLUSION: In this paper, we get sufficient soluble N terminal GST tagged RBD protein expressed in E. coli BL21 (DE3); data from ELISA and flow cytometry assay demonstrate that the recombinant protein is functional and binding to ACE2 positive Vero E6 cell efficiently. And the recombinant RBD derived from E. coli can be used to developing subunit vaccine to block S protein binding with receptor and to neutralizing SARS-Cov infection. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.

Crystallization and Structural Determination of the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein.

Cryo-electron Microscopy Structures of the SARS-CoV Spike Glycoprotein Reveal a Prerequisite Conformational State for Receptor Binding

Cryo-EM Structure of the SARS Coronavirus Spike Glycoprotein in Complex with Its Host Cell Receptor ACE2

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Structure of MERS-CoV Spike Receptor-Binding Domain Complexed with Human Receptor DPP4

Cryoelectron microscopy structures of a human neutralizing antibody bound to MERS-CoV spike glycoprotein

Crystallization and Preliminary Crystallographic Analysis of the Heptad-Repeat Complex of Sars Coronavirus Spike Protein

Complex Structure of Mers-Cov Spike Glycoprotein with Human Receptor Dpp4

Precise Location of Two Novel Linear Epitopes on the Receptor-Binding Domain Surface of MERS-CoV Spike Protein Recognized by Two Different Monoclonal Antibodies

Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein.

Computational Characterization and Design of SARS Coronavirus Receptor Recognition and Antibody Neutralization.

Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27

Structural Definition of a Neutralization Epitope on the N-terminal Domain of MERS-CoV Spike Glycoprotein

Bioinformatics Analysis on Potential Anti-Viral Targets Against Spike Protein of MERS-CoV

Functional reconstitution of the MERS CoV receptor binding motif

Receptor-binding Domain of SARS-Cov Spike Protein: Soluble Expression in E. Coli, Purification and Functional Characterization.

Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody

Synthetic Homogeneous Glycoforms of the SARS‐CoV‐2 Spike Receptor‐Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies

Characterization of the Heptad Repeat Regions, HR1 and HR2, and Design of a Fusion Core Structure Model of the Spike Protein from Severe Acute Respiratory Syndrome (SARS) Coronavirus.

A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain